PSS7 - QUALITY OF LIFE IMPROVEMENTS IN PSORIASIS WITH SECUKINUMAB IN A DIFFICULT TO TREAT POPULATION OF ANTI-TNF ALPHA FAILURE PATIENTS FROM THE UK AND REPUBLIC OF IRELAND

Abstract

Psoriasis can have a large impact on quality of life (QoL). Secukinumab, a fully human anti–interleukin-17A monoclonal antibody is licensed for the treatment of plaque psoriasis in adults who are candidates for systemic therapy. QoL results are presented from an open-label, non-comparator study that investigated the safety and efficacy of secukinumab in patients who previously failed anti-tumour necrosis factor (TNF) α biologic therapy. 235 eligible adults with active, moderate-to-severe, chronic plaque psoriasis from 53 sites in UK and Ireland were randomised 1:1 to receive secukinumab 300mg or 150mg subcutaneously for 72 weeks (dosing at weeks 0-4, then 4-weekly). Patients completed the Dermatology Life Quality Index (DLQI, range 0-30, higher scores reflecting worse QoL) and EuroQoL 5-Dimension Health Status Questionnaire (EQ-5D-5L) at baseline, weeks 12, 16, 24, 48 and 72. Results are presented for 118 patients on the dose of secukinumab licensed for psoriasis (300mg). At baseline, mean DLQI was 20.2 (SD=6.03). By week 16 this improved to 4.2 (SD=4.97). Improvements were maintained amongst patients remaining in the study; 4.2 (SD=5.90) at week 48 and 3.7 (SD=5.41) at week 72. Baseline EQ-5D-5L mean visual analogue score (VAS; range 0-100, lower scores reflecting worse QoL) was 54.9 (SD=24.84). By week 16 this improved to 76.3 (SD=21.58). Improvements were maintained amongst patients remaining in the study; 77.7 (SD=21.60) at week 48 and 78.2 (SD=19.80) at week 72. EQ-5D domains impacting the largest proportion of patients at baseline were pain/discomfort (90%; 106/118 patients) and anxiety/depression (77%; 91/118). By weeks 16, 48 and 72 respectively, fewer patients were reporting pain/discomfort; 53% (63/118), 43% (46/107) and 52% (43/83) and anxiety/depression; 38% (45/118), 36% (39/107) and 37% (31/83). These results demonstrate that secukinumab 300mg provides sustained QoL improvements even in a difficult to treat anti-TNFa failure population of psoriasis patients.